Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin

Blood

Volumn 93, Issue 10, 1999, Pages 3250-3258

  Miller, Langdon L ^a   Korn, Edward L ^b   Stevens, Diane S ^b   Janik, John E ^b   Gause, Barry L ^b   Kopp, William C ^b   Holmlund, Jon T ^b   Curti, Brendan D ^b   Sznol, Mario ^b   Smith II, John W ^b   Urba, Walter J ^b   Donegan, Sarah E ^b   Watson, Thelma M ^b   Longo, Dan L ^b  

^a PFIZER INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CHOLESTEROL; DRUG ANTIBODY; MILODISTIM;

ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; BONE MARROW TOXICITY; CANCER ADJUVANT THERAPY; CELL PROTECTION; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; IMMUNOGENICITY; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; MALE; NEUTROPHIL; PRIORITY JOURNAL; SKIN IRRITATION; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT; TREATMENT OUTCOME;

EID: 0033562815     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.10.3250.410k35_3250_3258     Document Type: Article

References (49)

1. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer (r-metHuG-CSF). N Engl J Med 325:164, 1991
2. Nemunaitis J, Rabinowe S, Singer J, Bierman PJ, Vose JM, Freedman AS, Onetto N, Gillis S, Oette D, Gold M: Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 324:1773, 1991
3. Hoffman R: Regulation of megakaryocytopoiesis. Blood 74:1196, 1989
4. Lindemann A, Ganser A, Herrmann F, Frish J, Seipelt G, Schulz G, Hoelzer D, Mertelsmann R: Biologic effects of recombinant human interleukin-3 in vivo. J Clin Oncol 9:2120, 1991
5. Ganser A, Lindemann A, Seipelt G, Ottman OG, Herrmann F, Eder M, Frisch J, Schulz G, Mertelsmann R, Hoelzer D: Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood 76:666, 1990
6. Stahl CP, Winton EF, Monroe MC, Haff E, Holman RC, Myers L, Liehl E, Evatt BL: Differential effects of sequential, simultaneous, and single-agent interleukin-3 and granulocyte-macrophage colony-stimulating factor on megakaryocyte maturation and platelet response in primates. Blood 80:2479, 1992
7. Ganser A, Lindemann A, Ottmann OG, Seipelt G, Hess U, Geissler G, Kanz L, Frisch J, Schulz G, Herrmann F, Mertelsmann R, Hoelzer D: Sequential in vivo treatment with two recombinant human hematopoietic growth factors (interleukin-3 and granuloctye-macrophage colony-stimulating factor) as a new therapeutic modality to stimulate hematopoiesis: Results of a phase I study. Blood 79:2583, 1992
8. Fay JW, Lazarus H, Herzig R, Saez R, Stevens DA, Collins RHJ, Pineiro LA, Cooper BW, DiCesare J, Campion M: Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: A phase I/II multicenter study. Blood 84:2151, 1994
9. Williams D, Park LS: Hematopoietic effects of a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein. Cancer 67:2705, 1991
10. Curtis BM, Williams DE, Broxmeyer HE, Dunn J, Farrah T, Jeffery E, Clevenger W, DeRoos P, Martin U, Friend D, Craig V, Gayle R, Price V, Cosman D, March CJ, Park LS: Enhanced hematopoietic activity of a human granulocyte/macrophage colony-stimulating factor-interleukin 3 fusion protein. Proc Natl Acad Sci USA 88:5809, 1991
11. Bruno E, Briddell RA, Cooper RJ, Brandt JE, Hoffman R: Recombinant GM-CSF/IL-3 fusion protein: Its effect on in vitro human megakaryocytopoiesis. Exp Hematol 20:494, 1992
12. Williams DE, Farese A, Dunn J, Freiden E, Park LS, MacVittie TJ: In vivo effects of a GM-CSF/IL-3 fusion protein (PIXY321) in sublethally irradiated monkeys. Exp Hematol 19:584, 1991 (abstr)
13. Gabrilove JL, Jakubowski A, Fain K: Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest 82:1454, 1988
14. Steis RG, Vandermolen LA, Longo DL, Clark JW, Smith JW, Kopp WC, Ruscetti FW, Creekmore SP, Elwood LJ, Hursey J: Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: A phase Ib trial. J Natl Cancer Inst 82:697, 1990
15. Phillips N, Jacobs S, Stoller R, Earle M, Przepiorka D, Shadduck RK: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in patients with refractory metastatic carcinoma. Blood 74:26, 1989
16. Vadhan-Raj S, Broxmeyer HE, Hittelman WN, Papadopoulos NE, Chawla SP, Fenoglio C, Cooper S, Buescher ES, Frenck RW, Holian A, Perkins RC, Scheule RK, Gutterman JU, Salem P, Benjamin RS: Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: Protection at the progenitor cell level. J Clin Oncol 10:1266, 1992
17. Neidhart JA, Mangalik A, Stidley CA, Tebich SL, Sarmiento LE, Pfile JE, Oette DH, Oldham FB: Dosing regimen of granulocyte-macrophage colony-stimulating factor to support dose-intensive chemotherapy. J Clin Oncol 10:1460, 1992
18. O'Reilly SE, Gelmon KA, Onetto N, Parente J, Rubinger M, Page RA, Plenderleith IH: Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil. J Clin Oncol 11:2411, 1993
19. Rusthoven JJ, Eisenhauer E, Mazurka J, Hirte H, O'Connell G, Muldal A, Lu HX, Onetto N, Swenerton K, Jeffrey J: Phase I clinical trial of recombinant human interleukin-3 combined with carboplatin in the treatment of patients with recurrent ovarian carcinoma. J Natl Cancer Inst 85:823, 1993
20. Biesma B, Willemse PHB, Mulder NH, Sleijfer DT, Gietema JA, Mull R, Limburg PC, Bouma J, Vellenga E, deVries EG: Effects of interleukin-3 after chemotherapy for advance ovarian cancer. Blood 80:1141, 1992
21. Veldhuis GJ, Willemse PH, van Gameren MM, Aalders JG, Mulder NH, Mull B, Biesma B, de Vries EG: Recombinant human interleukin-3 to dose-intensify carboplatin and cyclophosphamide chemotherapy in epithelial ovarian cancer: A phase I trial. J Clin Oncol 13:733, 1995
22. D'Hondt V, Weynants P, Humblet Y, Guillaume T, Canon JL, Beauduin M, Duprez P, Longueville J, Mull R, Chatelain C: Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: A placebo-controlled randomized phase Ib study. J Clin Oncol 11:2063, 1993
23. Aglietta M, Sanavio F, Stacchini A, Morelli S, Fubini L, Severino A, Pasquino P, Volta C, Bretti S, Tafuto S: Interleukin-3 in vivo: Kinetics of response of target cells. Blood 82:2054, 1993
24. Nash RA, Burstein SA, Storb R, Yang W, Abrams K, Appelbaum FR, Boone T, Deeg HJ, Durack LD, Schuening FG: Thrombocytopenia in dogs induced by granulocyte-macrophage colony-stimulating factor: Increased destruction of circulating platelets. Blood 86:1765, 1995
25. Vadhan-Raj S, Papadopoulos NE, Burgess MA, Linke KA, Patel SR, Hays C, Arcenas A, Plager C, Kudelka AP, Hittelman WN: Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma. J Clin Oncol 12:715, 1994
26. Herrmann F, Schulz G, Lindemann A, Meyenburg W, Oster W, Krumwieh D, Mertelsmann R: Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor. J Clin Oncol 7:159, 1989
27. Gianni AM, Siena S, Bregni M, DiNicola M, Peccatori F, Magni M, Ravagnani F, Sklenar I, Bonadonna G: Recombinant human interleukin-3 hastens trilineage hematopoieitic recovery following high-dose (7 g/m2) cyclophosphamide cancer therapy. Ann Oncol 4:759, 1993
28. Brugger W, Frisch J, Schulz G, Pressler K, Mertelsmann R, Kanz L: Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin. J Clin Oncol 10:1452, 1992
29. Steis RG, Smith JW, Urba WJ, Clark JW, Itri LM, Evans LM, Schoenberger C, Longo D: Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med 318:1409, 1988
30. Whitehead RP, Ward D, Hemingway L, Hemstreet GP, Bradley E, Konrad M: Subcutaneous recombinant interleukin-2 in a dose-escalating regimen in patients with metastatic renal cell adenocarcinoma. Cancer Res 50:6708, 1990
31. Scharenberg JGM, Stam AGM, von Blomberg BME, Roest GJ, Palmer PA, Franks CR, Meijer CJLM, Scheper RJ: The development of anti-interleukin-2 (IL-2) antibodies in cancer patients treated with recombinant IL-2. Eur J Cancer 30A: 1804, 1994
32. Ragnhammar P, Friesen H-J, Frodin J-E, Lefvert A-K, Hassan M, Osterborg A, Mellstedt H: Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coliderived) antibodies and clinical effects in non-immunocompromised patients. Blood 84:4078, 1994
33. Ragnhammar P, Fagerberg J, Frodin JE, Wersall P, Hansson LO, Mellstedt H: Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies. Cancer Immunol Immunother 40:367, 1995
34. Hammond WP, Csiba E, Canin A, Hockman H, Souza LM, Layton JE, Dale DC: Chronic neutropenia: A new canine model induced by human granulocyte colony-stimulating factor. J Clin Invest 87:704, 1991
35. Amgen discontinues MGDF platelet donation trials. Amgen Press Release. August 18, 1998
36. Caux C, Liu Y-J, Banchereau J: Recent advances in the study of dendritic cells and follicular dendritic cells. Immunol Today 16:2, 1995
37. Morrissey PJ, Bressler L, Park LS, Alpert A,Gillis S: Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J Immunol 139:1113, 1987
38. Tao MH, Levy R: Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362:755, 1993
39. Furman WL, Marina N, Luo X, Arnold B, Pratt C, Bowman LC, Santana V, Garrison L, Meyer W: A pediatric phase I/II trial of subcutaneous (SC) PIXY321 administered after ifosfamide/carboplatin/ etoposide (ICE) chemotherapy. Proc Am Soc Clin Oncol 13:418, 1994 (abstr)
40. Runowicz CD, Mandeli J, Speyer JL, Wadler S, Hochster H, Garrison L, Holland JF: Phase I/II study of PIXY321 in combination with cyclophosphamide and carboplatin in the treatment of ovarian cancer. Am J Obstet Gynecol 174:1151, 1996
41. Raptis G, Gilewski T, Gabrilove J, Schuster S, Crown J, Hudis C, Seidman A, Caron D, Norton L, Jakubowski A: Evaluation of PIXY321 (PIXY) as a myeloprotective agent in patients (pts) with metastatic breast cancer receiving doxorubicin and thiotepa. Proc Am Soc Clin Oncol 12:108, 1993 (abstr)
42. Cairo MS, Weinthal JA, Garrison L, Krailo M, Kao WW, Sender LS, Blazar B, Reaman G: Results of a phase I trial of PIXY321 following ifosfamide, carboplatin, and etoposide (ICE) chemotherapy in children with recurrent solid tumors (RST): Improved multi-lineage hematopoietic reconstitution. Proc Am Soc Clin Oncol 14:255, 1995 (abstr)
43. Vose JM, Anderson JE, Bierman PJ, Appelbaum FR, Anderson JR, Garrison L, Lebsack ME, Armitage JO: Phase I/II trial of PIXY321 to enhance engraftment following autologous bone marrow transplantation for lymphoid malignancy. J Clin Oncol 14:520, 1996
44. Neidhart JA: PIXY321 support of chemotherapy with carboplatin and dose-intensive cytoxan, VP-16, and cisplatin. Cancer Invest 12:19, 1994 (abstr, suppl 11)
45. Vose JM, Pandite L, Beveridge RA, Geller RB, Schuster MW, Anderson JE, LeMaistre CF, Lebsack ME: Phase III study comparing PIXY321 and GM-CSF following autologous bone marrow transplantation (ABMT) in patients with non-Hodgkin's lymphoma (NHL). Blood 86:972a, 1995 (abstr, suppl 1)
46. Ellis GK, Hutchins L, Jimenez-Martin M, Pecora AL, Barnadas A, Meisenberg B, Nabholtz JM, Cortes-Funes H, Rifkin R, Chang AYC, Garrison L, George C, Giles FJ: Phase III double-blind randomized study of PIXY321 verus G-CSF after CEP for breast or ovarian carcinoma. Blood 88:449a, 1996 (abstr, suppl 1)
47. Nantel SH, Bernstein SH, Stevens DA, Fay JW, Herzig RH, Phillips GL, Herzig GP, Garrison L: Dose-escalation study of PIXY321 post autologous bone marrow transplant (BMT) for Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL). Blood 86:222a, 1995 (abstr, suppl 1)
48. O'Shaughnessy JA, Tolcher A, Riseberg D, Venzon D, Zujewski J, Noone M, Gossard M, Danforth D, Jacobson J, Chang V, Goldspiel B, Keegan P, Giusti R, Cowan KH: Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer. Blood 87:2205, 1996
49. Vancurova M, Prochazkova J, Novakova M, Blahuta Z: Platinum cytostatics influence the primary antibody response of mouse spleen cells in vitro. Neoplasma 34:277, 1987